Development and Validation of a Stability-Indicating RP-HPLC Method for Gilteritinib Using a Quality by Design
Journal of Pharma Insights and Research · 05.06.2026 · 4 (3) · 313-325
DOI: 10.69613/76qgjh07 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharma Insights and Research, online erschienen am 05.06.2026. Verfasst von Meghana Sunkara und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
A robust, stability-indicating reversed-phase high-performance liquid chromatography method was developed and validated for the quantitative determination of the dual FLT3/AXL inhibitor gilteritinib in pharmaceutical dosage forms utilizing an analytical Quality by Design framework. Separation was achieved on a Phenomenex column (150 4.6 mm, 5 µm) with a mobile phase composed of 0.01 M potassium dihydrogen phosphate buffer (adjusted to pH 3.0 containing 0.1% v/v triethylamine) and acetonitrile in a 59:41 v/v ratio. Chromatographic conditions were systematically optimized utilizing a three-factor, three-level Central Composite Design to evaluate the impact of flow rate, column temperature, and organic modifier concentration on critical quality attributes, including retention time, theoretical plates, and peak asymmetry. Under optimal conditions of 0.93 mL/min flow rate and 27°C column temperature, gilteritinib eluted as a symmetrical peak at 2.66 min. The method showed a linear response over the concentration range of 10 to 60 µg/mL with a high correlation coefficient of 0.999. The limits of detection and quantitation were determined to be 0.17 µg/mL and 0.53 µg/mL, respectively. Forced degradation studies conducted under hydrolytic, oxidative, photolytic, and thermal stress conditions showed that the method effectively resolved gilteritinib from its primary degradation products eluting at 1.65 and 2.99 min, confirming its stability-indicating capability. Application to commercial formulations resulted in a quantitative drug recovery of 100.25%, showing excellent precision and accuracy for high-throughput pharmaceutical quality control
Zitieren
APA
Sunkara, M., Appala, A., & Ponnaganti, S. P. K. (2026). Development and Validation of a Stability-Indicating RP-HPLC Method for Gilteritinib Using a Quality by Design. Journal of Pharma Insights and Research, 4(3), 313-325. https://doi.org/10.69613/76qgjh07
Vancouver
Sunkara M, Appala A, Ponnaganti SPK. Development and Validation of a Stability-Indicating RP-HPLC Method for Gilteritinib Using a Quality by Design. Journal of Pharma Insights and Research. 2026;4(3):313-325. doi:10.69613/76qgjh07
BibTeX
@article{Sunkara2026,
author = {Sunkara, Meghana and Appala, Anjali and Ponnaganti, SS Prasanna Kumar},
title = {Development and Validation of a Stability-Indicating RP-HPLC Method for Gilteritinib Using a Quality by Design},
journal = {Journal of Pharma Insights and Research},
year = {2026},
volume = {4},
number = {3},
pages = {313--325},
doi = {10.69613/76qgjh07}
}
EUVIMED